FHACT® takes the guess work out of cervical cancer screening

WATCH THE VIDEO >

Get answers,
get FHACT®.
Webinar series.

LEARN MORE >

FHACT® is indicated for HPV-positive ASCUS and LSIL patients.

LEARN MORE >

FHACT® is the only FISH Probe to assess four biomarkers associated with cervical cancer.

Learn More

Latest News

17 Jan 17

Precision Oncology Diagnostics Leader, Cancer Genetics, Inc. & Precision Therapeutics Company, Lantern Pharma, Inc. Announce Strategic Collaboration Focused on Drug Rescue & Repurposing Leveraging Genomics, Biomarkers & Artificial Intelligence Driven Development for Multiple Lead Oncology Compounds (read more...)

- The collaboration will leverage CGI’s biomarker discovery, clinical trial testing, and companion diagnostic development capabilities along with (read more...)
09 Jan 17

Cancer Genetics, Inc. Announces Multiple Agreements & Collaborations to Develop Liquid Biopsy Programs with Leading Biopharma Companies (read more...)

- CGI has signed five agreements and contracts to develop focused, high-performance liquid biopsy tests for a broad range of solid tumors The liquid(read more...)

Events

Clinicians
Patients